Results 311 to 320 of about 775,670 (354)

EGFR blockade activates interferon

Nature Cancer, 2020
Dysregulation of innate immune signaling in cancer can be pro-tumorigenic and can promote adaptive resistance to targeted therapies. Type I interferon signaling is now shown to promote survival following inhibition of the kinase EGFR, even in cells that are not ‘addicted’ to EGFR signaling.
Ryohei Yoshida, David A. Barbie
openaire   +2 more sources

A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.

Bioorganic chemistry (Print), 2020
The identification of molecular agents inhibiting specific functions in cancer cells progression is considered as one of the most successful plans in cancer treatment.
Adile Ayati, S. Moghimi, Somayeh Salarinejad, M. Safavi, Behjat Pouramiri, A. Foroumadi   +5 more
semanticscholar   +1 more source

Overcoming therapy resistance in EGFR-mutant lung cancer

Nature Cancer, 2021
A. Passaro, P. Jänne, T. Mok, S. Peters
semanticscholar   +1 more source

EGFR activation limits the response of liver cancer to lenvatinib

Nature, 2021
Haojie Jin, Yaoping Shi, Yuanyuan Lv, S. Yuan, C. Ramirez, C. Lieftink, Liqin Wang, Siying Wang, Cun Wang, M. Dias, F. Jochems, Yuan Yang, A. Bosma, E. M. Hijmans, Marnix H. P. de Groot, S. Vegna, D. Cui, Yangyang Zhou, Jing Ling, Hui Wang, Yuchen Guo, Xing-ling Zheng, Nikita Isima, Haiqiu Wu, Chong Sun, R. Beijersbergen, L. Akkari, Weiping Zhou, B. Zhai, Wenxin Qin, R. Bernards   +30 more
semanticscholar   +1 more source

EGFR mutations and EGFR tyrosine kinase inhibitors

The Lancet Oncology, 2015
Valter, Torri, Massimo, Broggini, Marina Chiara, Garassino   +2 more
openaire   +2 more sources

EGFR Mutant Lung Cancer

2011
Thoracic oncologists traditionally have made treatment decisions based upon tumor histology, distinguishing non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). However, recent data has revealed that at least one histological subtype of NSCLC, lung adenocarcinoma comprises multiple molecularly distinct diseases.
Yixuan, Gong, William, Pao
openaire   +2 more sources

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

The Lancet Oncology, 2012
R. Rosell, E. Carcereny, R. Gervais, A. Vergnenègre, B. Massutí, E. Felip, R. Palmero, R. García-Gómez, C. Pallarés, J. Sánchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Morán, A. Insa, F. de Marinis, R. Corre, I. Bover, A. Illiano, É. Dansin, J. de Castro, M. Milella, N. Reguart, G. Altavilla, U. Jiménez, M. Provencio, M. Moreno, J. Terrasa, J. Muñoz-Langa, J. Valdivia, D. Isla, M. Dómine, O. Molinier, J. Mazières, N. Baize, R. García-Campelo, G. Robinet, D. Rodríguez-Abreu, G. López-Vivanco, V. Gebbia, Lioba Ferrera-Delgado, P. Bombaron, R. Bernabé, A. Bearz, Á. Artal, E. Cortesi, C. Rolfo, M. Sánchez-Ronco, A. Drozdowskyj, C. Queralt, I. de Aguirre, J. Ramírez, J. Sánchez, M. Molina, M. Taron, L. Paz-Ares   +56 more
semanticscholar   +1 more source

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

The Lancet Oncology, 2011
Caicun Zhou, Yi-long Wu, Gongyan Chen, Jifeng Feng, Xiao‐qing Liu, Chang-li Wang, Shucai Zhang, Jie Wang, Songwen Zhou, S. Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, M. Ye, Jianan Huang, X. Zhi, Yiping Zhang, Q. Xiu, Jun Ma, C. You   +22 more
semanticscholar   +1 more source

Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR–STAT3 signalling

Nature Cell Biology, 2021
Xinya Gao, Xin Xia, Fanying Li, Maolei Zhang, Huangkai Zhou, Xujia Wu, J. Zhong, Zheng Zhao, Kun Zhao, Dawei Liu, Feizhe Xiao, Qiang Xu, Tao Jiang, Bo Li, Shi-Yuan Cheng, Nu Zhang   +15 more
semanticscholar   +1 more source

EGFR

1995
Klaus Seedorf, Axel Ullrich
openaire   +1 more source